Control Bionics
Control Bionics develops assistive technology, including speech generating devices, to help individuals with complex communication and physical needs. Their products, such as the NeuroNode Trilogy and EyeGaze Duo, offer innovative access methods for enhanced communication.
Services
Control Bionics develops accessible assistive technology to aid people living with complex communication and physical needs. The company offers various speech generating devices tailored to different access methods. Products include NeuroNode Trilogy, NeuroNode Duo, EyeGaze Duo, Uno Touch, and Cosmos Connect. Control Bionics also provides funding through multiple channels such as Medicare, Medicaid, the Veterans Health Administration, private insurance, and educational systems in the USA. The company supports customers with 24/7 technical assistance via email, phone, or virtual visits.
Products
Control Bionics offers a range of products designed to assist those with communication disabilities. The NeuroNode Trilogy combines touch, eye control, and EMG/Spatial control for a multifaceted speech generating device. The NeuroNode Duo is another speech generating device with varied access methods. The EyeGaze Duo leverages touch or eye gaze for streamlined communication. The Uno Touch is a lightweight, robust device, while the Cosmos Connect is a portable control device for use with Windows display devices. The NeuroNode stands out as the only wireless, wearable sensor that accesses technology via bioelectric signals or spatial movements.
Technology
Control Bionics uses bioelectric signal and spatial movement technologies to create devices that assist individuals with paralytic conditions and loss of speech. The NeuroNode, a core product, is an FDA-registered medical device that serves as a wireless, wearable sensor. Other devices such as the NeuroNode Trilogy integrate multiple access methods—touch, eye control, and EMG/Spatial—offering flexible solutions for complex needs. Control Bionics emphasizes the use of cutting-edge assistive technology aimed at providing more autonomy to users.
Global Presence
Control Bionics operates offices in multiple countries including the USA, Australia, Canada, and Japan. This global presence allows the company to cater to a broad client base and provide localized support services. The international reach also facilitates the company's mission to help as many people as possible regain control over their environments through advanced assistive technology.
Recognition and Funding
In 2023, Control Bionics received a prestigious Assistive Technology Grant from the ALS Association, highlighting the company's innovations in the field. The products developed by Control Bionics are billed using HCPC’s code E2510 and E2599, making them accessible through various funding sources such as Medicare, Medicaid, Veterans Health Administration, private insurance, and education systems in the USA.